All the research and analysis done for you, summed up in sharp slides. Forget boring reports and "trust us" insights with no methodology behind them. We’ve transformed complex information into clear, accessible insights.
12 sections to help founders and investors understand
the healthcare AI with clarity
Before talking numbers, we show the market "box" we’re using: what goes in the box, what stays out, what’s inside as segments, and what sits next to it.
We do this because every chart in the deck depends on that definition.
It helps you understand all the data in this deck (and there is a lot) without second-guessing what they mean.
Tighter rules, clearer pathways, more progress - the healthcare AI market is both hot and maturing in 2026.
We have identified strong positive signals. FDA publishing concrete "how to submit AI devices" guidance, Epic (the dominant EHR) moving into AI scribing or Abridge raising a huge round tied to real deployments are some of them.
In this section, we will see why now is a good time to build and invest in this market.
You’ll find a lot of different estimates online for healthcare AI size and CAGR … and honestly, it’s hard to trust most of them. Many also use market definitions that don’t match ours.
This deck gives you a clear, defensible estimate. We start with first-principles analysis, verify it with aggregated sources, and document every assumption. We also show the reasoning behind the result so you can pressure-test it yourself.
The point is to give you numbers you can trust ... and a fast sanity check on whether this market is worth pursuing.
If healthcare AI is surging, it's also because the problems are overwhelming.
Hospitals, clinicians, insurers, and patients all struggle with inefficiencies that intelligent systems can fix. We will show you in this section who the stakeholders are and what's pushing them toward AI adoption.
Understanding these pain points will help you create or invest in solutions that improve care and deliver real ROI.
If you're interested in healthcare AI, you know how rapidly this space is advancing ... new models, new applications, new regulatory milestones every few months.
We regularly update this section to reflect what's live, what's in clinical trials, and what's being developed.
In this section, we're covering diagnostic AI, clinical decision support, drug discovery tools, administrative automation, and the platforms enabling it all.
You need to understand where healthcare AI creates measurable value (and who owns the budget) before you assume “better outcomes” will automatically translate into revenue.
We will give you clarity on which business models are working right now, and why some segments deliver 10x better unit economics than others.
You will see how the winners monetize through reimbursement, provider and payer contracts, workflow software, and risk-sharing ... and how to avoid products that get praised in pilots but never scale in procurement.
There are the risks you’ve heard of and everyone knows in healthcare AI: slow hospital buying, heavy compliance, and hard integrations, among other factors.
But there are other things to keep in mind, like models getting worse over time, unclear liability when errors happen, and clinician pushback if the tool adds work.
In this section, we map the challenges and how likely they are, so you can plan ahead before you invest or build.
As mentioned earlier, we will give you a realistic growth rate for the healthcare AI market. Now we also need to explain why the market would grow. If we do not, the numbers are just guesswork.
Some drivers are easy to see: pressure to reduce costs, clinician shortages, and better model performance in imaging, documentation, and triage. But there are also less obvious forces that can accelerate healthcare AI, including integration into clinical workflows, clearer evidence standards, regulatory clarity, improved data access and interoperability, and payment models that reward measurable outcomes.
Before building or investing, you should know what these forces are, and what needs to happen for them to kick in at scale.
Not every investor is chasing the same thing. In healthcare AI, the strongest conviction is clustering around products that fit clinical workflows, show measurable outcomes, and can clear real-world adoption hurdles.
In this section, we’ll show you where capital is actually going right now. You’ll see which companies are raising, plus the pattern behind the rounds: the use cases investors are leaning into, what they’re passing on, and the newer theses starting to build momentum across data, deployment, and reimbursement.
Use this to stay aligned with what capital is rewarding today.
You already know Tempus and Aidoc, but a new wave of promising startups is emerging across healthcare AI.
They rarely dominate the headlines. Many are building quietly, outside the spotlight. But they are worth watching, and a few may become breakout winners.
Because the category is still early, confusion is common, especially around clinical validation, workflow adoption, and reimbursement.
That’s why, in this section, we’ll share the detailed market grids and ecosystem maps we’ve built, so you can quickly see what’s happening, where the opportunities are, and how healthcare AI is evolving.
Healthcare AI isn’t a guaranteed goldmine. Many founders underestimate how unforgiving this industry is: data access, clinical validation, reimbursement, procurement cycles, and regulatory scrutiny, and some crash hard.
So we studied healthcare AI startups that failed and pulled out the non-obvious patterns: the quiet traps you don’t see in generic startup advice, like training on the wrong data, skipping workflow adoption, misreading who actually pays, or promising outcomes you can’t defend.
The goal: if you’re building, you start ahead. If you’re investing, you avoid teams heading toward the same dead ends.
Tempus, Viz.ai, Aidoc… healthcare AI is starting to produce real winners.
So what made them credible when “AI in healthcare” is infamous for hype? How did they earn clinician trust, navigate regulation, and embed into day-to-day workflows where budgets actually live? There are a few recurring moves worth noticing.
We’ve studied the teams that shipped outcomes (not just models) and we’ll lay out the cheat codes in this section so you can apply the same logic to your own product.
This deck is built for founders, investors, operators, and strategists who need a clearer view of the market before they build, invest, partner, or reposition.
It is especially useful if you are trying to understand where the opportunity is real, how the market is evolving, and what separates the promising segments from the fragile ones.
The deck is around 210+ pages. It is designed to be comprehensive enough to support serious market evaluation, while still being fast to read and easy to use.
We prioritize signal, structure, and visual clarity over unnecessary length.
We define the healthcare AI market as AI software and models used by healthcare providers, payers, life sciences companies, medtech firms, and public health bodies to improve clinical care, operations, and research.
We include clinical decision support, diagnostic and monitoring tools, hospital and clinic workflow and revenue cycle automation, payer analytics and claims tools, as well as AI used in pharma and biotech R&D, clinical trials, and connected medical devices.
We exclude general-purpose AI infrastructure, pure consumer wellness and fitness apps, and horizontal enterprise tools that are not purpose-built or primarily sold for healthcare use.
Yes. All key data points and assumptions are explained and sourced in the deck.
All sources are tier-1: company filings, funding databases, public datasets, expert interviews, industry reports, etc.
Yes. The deck was last updated on June 5, 2026 with the latest market signals.
Yes. This is a one-time purchase. There is no subscription required to access the deck.
Yes. You can use NEWMARKET for 20% off when purchasing two reports, or NEWMARKETMAX for 30% off when purchasing five or more.
If a market you care about is not currently on the list, email us at team@newmarketpitch.com and we may be able to cover it.
No problem. You can reach out directly and we respond within 24 hours.
The cost of misreading a market is high, especially in a category as nuanced as this one. This deck helps you understand where the market is real, where it is moving, and what matters most before you commit time, capital, or strategy
